FINO
FINAL DECISION TRANSACTION PROCESSED BY IB
14/08/2023
Voltar para busca
Dado oficial do USPTO
CYTED
Sabia que essa marca já está registrada no Estados Unidos?
Antes de investir em nome, identidade e divulgação, valide risco de colisão e estratégia de registro para não perder tempo nem budget.
Active USPTO registrationTipo: MistaEscritório: US
Diagnóstico de risco e oportunidade
Leitura executiva para decisão de naming, protocolo e monitoramento.
Situação USPTO
Active USPTO registration
Tipo de processo
Pedido e registro
Eventos registrados
38
Atualização mais recente
14/08/2023
Classificação
Registrada
Tipo de marca
Mista
Classes Nice
9, 10, 42, 44
Data de depósito
22/03/2021
Data de registro
04/04/2023
Data de expiração
-
Ação recomendada
Execute uma análise de colidência completa e valide classes antes de qualquer protocolo ou investimento de marca.
Próximo passo
Esses são os detalhes do processo de registro. Mesmo assim, o monitoramento constante é o que garante tranquilidade de que o seu principal ativo continue protegido.
Dados completos do processo
Campos estruturados da autoridade responsável e do histórico oficial.
Data da situação
04/04/2023
Última transação
04/04/2023
Escritório responsável
United States Patent and Trademark Office
Código da situação
700
Cadastro oficial
Principal Register
Código do desenho
3
Tipo de titular
99
Localização do titular
GB
Examinador
BLAZICH, JOAN MICHELE
Unidade examinadora
N40
Localização atual
PUBLICATION AND ISSUE SECTION
Descrição da marca
The mark consists of a cuboctahedron shape and the word "CYTED".
Titulares e representantes
Titulares
Cyted Ltd
Representantes
Michael R. Friscia McCarter & English, LLP
Classificação técnica
Classes Nice
Classe 9Classe 10Classe 42Classe 44
Códigos Vienna
Sem códigos Vienna disponíveis.
Produtos e serviços
Classe 9
Downloadable computer software for cancer and gastrointestinal disease screening and diagnostic purposes for use in medical decision support systems
Classe 10
Diagnostic imaging apparatus for medical use; diagnostic testing apparatus for use in medical immunoassay procedures; diagnostic testing apparatus for use in medical molecular analyses; diagnosticexaminationmonitoring equipment for medical use and pathologyfor cancer and gastrointestinal disease; diagnostic instruments for medical use for pathology for detecting cancer and gastrointestinal disease; diagnostic measuring apparatus for medical use and pathologyfor cancer and gastrointestinal disease; medical diagnostic apparatus for medical purposes and pathologyfor cancer and gastrointestinal disease; medical diagnostic instruments for medical use for pathologyfor cancer and gastrointestinal disease
Classe 42
Medical laboratories; medical and pharmacological research services; medical laboratory services; medical research; medical research laboratory services; medical research services; software as a service (SaaS) services featuring software for identifying markers for screening and diagnostic purposes for cancer and gastrointestinal disease; software creation; software customisation services; software design; software design and development; biomedical research services; design and development of medical technology; design and development of computer software for use with medical technology; platforms for artificial intelligence as software as a service (SaaS)software as a service (SaaS) services featuring software for identifying markers for screening and diagnostic purposes for cancer and gastrointestinal disease; database design and development; design and development of computer database programs and software; design and development of computer software for use with medical technologylogisticsreading datasupply chain management; design and development of computer software architecture; design and development of data display entry and output systemsdata processing apparatusprogrammessoftware and systems; design and development of diagnostic apparatus
Classe 44
Medical services; medical testingscreening and diagnostic services for cancer and gastrointestinal disease; medical diagnostic testingmonitoring and reporting services; medical testing for diagnostic or treatment purposes; medical testing services relating to the diagnosis and treatment of disease; medical advisory services; medical treatment servicesfor pathology; arranging of medical treatmentproviding medical diagnostic testingmonitoring and reporting services for pathology in the field of cancer and gastrointestinal disease; medical analysis services for diagnostic and treatment purposes provided by medical laboratories; performing diagnosis of diseases; medical services for the diagnosis of conditions of the human body; medical analysis services for cancer and gastrointestinal diseasescreening and diagnostics; medical examination of individuals; medical and healthcare clinics being facilities with access for patients; providing medical information regarding testing and diagnosis of diseases and infections; providing medical information regarding diagnosis and treatment of diseases and infections; medical analysis services for cancer diagnosis and prognosis; medical analysis services relating to the treatment of patients and persons; medical analysis servicesfor screening and diagnostic purposes provided by medical laboratories; medical laboratory services for the analysis of samples taken from patients; medical services relating to the removaltreatment and processing of human cells; computer aided medical diagnostic testing services
Publicações
Histórico de despachos e eventos da marca no USPTO.
38 publicações encontradas
ADCH
CHANGE OF NAME/ADDRESS REC'D FROM IB
23/07/2023
FICS
FINAL DISPOSITION NOTICE SENT TO IB
20/07/2023
FIMP
FINAL DISPOSITION PROCESSED
20/07/2023
FICR
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
04/07/2023
NREP
NEW REPRESENTATIVE AT IB RECEIVED
21/04/2023
NRCC
NOTICE OF REGISTRATION CONFIRMATION EMAILED
04/04/2023
R.PR
REGISTERED-PRINCIPAL REGISTER
04/04/2023
GPNX
NOTIFICATION PROCESSED BY IB
24/01/2023
NPUB
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
17/01/2023
PUBO
PUBLISHED FOR OPPOSITION
17/01/2023
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
04/01/2023
OP2R
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
04/01/2023
NONP
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
28/12/2022
CNSA
APPROVED FOR PUB - PRINCIPAL REGISTER
12/12/2022
ATRV
ATTORNEY REVIEW COMPLETED
12/12/2022
OPNX
NOTIFICATION OF POSSIBLE OPPOSITION - PROCESSED BY IB
27/11/2022
ERFR
TEAS REQUEST FOR RECONSIDERATION RECEIVED
23/11/2022
EXPI
EX PARTE APPEAL-INSTITUTED
23/11/2022
JURT
JURISDICTION RESTORED TO EXAMINING ATTORNEY
23/11/2022
EXAF
EXPARTE APPEAL RECEIVED AT TTAB
23/11/2022
OPNS
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
09/11/2022
OPNR
NOTIFICATION OF POSSIBLE OPPOSITION CREATED, TO BE SENT TO IB
09/11/2022
GNFN
NOTIFICATION OF FINAL REFUSAL EMAILED
06/06/2022
GNFR
FINAL REFUSAL E-MAILED
06/06/2022
CNFR
FINAL REFUSAL WRITTEN
06/06/2022
TEME
TEAS/EMAIL CORRESPONDENCE ENTERED
31/05/2022
CRFA
CORRESPONDENCE RECEIVED IN LAW OFFICE
31/05/2022
TROA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
31/05/2022
RFNT
REFUSAL PROCESSED BY IB
19/12/2021
RFCS
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
29/11/2021
RFRR
REFUSAL PROCESSED BY MPU
29/11/2021
RFCR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
28/10/2021
CNRT
NON-FINAL ACTION WRITTEN
27/10/2021
DOCK
ASSIGNED TO EXAMINER
26/10/2021
MAFR
APPLICATION FILING RECEIPT MAILED
11/06/2021
NWOS
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
07/06/2021
REPR
SN ASSIGNED FOR SECT 66A APPL FROM IB
03/06/2021
Proteção contínua da sua marca
Seja avisado a cada novo depósito que ameace CYTED ou a sua marca.
Vigilância profissional por 24 meses: monitoramos o USPTO por você e alertamos a tempo de você se opor — antes que o conflito vire prejuízo.